Fr. 134.00

Aromatase Inhibitors

English · Paperback / Softback

Shipping usually within 1 to 2 weeks (title will be printed to order)

Description

Read more

Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase).
Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.

List of contents

Background and development of aromatase inhibitors.- Aromatase inhibitors and models for breast cancer.- Clinical pharmacology of aromatase inhibitors.- Clinical studies with exemestane.- Clinical studies with letrozole.- Clinical studies with anastrozole.- The third-generation aromatase inhibitors: a clinical overview.- Lessons from the ArKO mouse.- Possible additional therapeutic uses of aromatase inhibitors.

About the author

William R. Miller ist ein US-amerikanischer Psychologe, emeritierter Professor der University of New Mexico in Albuquerque sowie gemeinsam mit Stephen Rollnick Begründer der Motivierenden Gesprächsführung.

Summary

Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase).
Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.

Product details

Assisted by B. J. A. Furr (Editor), B.J.A. Furr (Editor), Barrington J. A. Furr (Editor), J A Furr (Editor), B J A Furr (Editor)
Publisher Springer, Basel
 
Languages English
Product format Paperback / Softback
Released 07.03.2012
 
EAN 9783764386924
ISBN 978-3-7643-8692-4
No. of pages 189
Illustrations X, 189 p.
Series Milestones in Drug Therapy
Milestones in Drug Therapy
Subject Natural sciences, medicine, IT, technology > Medicine > Non-clinical medicine

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.